No description available.

The aim of this study was to characterize the ophthalmic and genetic features of Bardet Biedl (BBS) syndrome in a cohort of patients from a German specialized ophthalmic care center. Sixty-one patients, aged 5–56 years, underwent a detailed ophthalmic examination including visual acuity and color vision testing, electroretinography (ERG), visually evoked potential recording (VEP), fundus examination, and spectral domain optical coherence tomography (SD-OCT). Adaptive optics flood illumination ophthalmoscopy was performed in five patients. All patients had received diagnostic genetic testing and were selected upon the presence of apparent biallelic variants in known BBSassociated genes. All patients had retinal dystrophy with morphologic changes of the retina. Visual acuity decreased from ~0.2 (decimal) at age 5 to blindness 0 at 50 years. Visual field examination could be performed in only half of the patients and showed a concentric constriction with remaining islands of function in the periphery. ERG recordings were mostly extinguished whereas VEP recordings were reduced in about half of the patients. The cohort of patients showed 51 different likely biallelic mutations—of which 11 are novel—in 12 different BBS-associated genes. The most common associated genes were BBS10 (32.8%) and BBS1 (24.6%), and by far the most commonly observed variants were BBS10 c.271dup;p.C91Lfs*5 (21 alleles) and BBS1 c.1169T>G;p.M390R (18 alleles). The phenotype associated with the different BBS-associated genes and genotypes in our cohort is heterogeneous, with diverse features without genotype–phenotype correlation. The results confirm and expand our knowledge of this rare disease.

No description available.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2007. / Härtill 4 uppsatser.

Répondant au besoin de mieux comprendre les relations qui lient un génotype aux phénotypes moléculaires et cliniques associés, nous avons développé une nouvelle infrastructure bioinformatique qui unit, dans un même système, la collecte, la gestion, la maintenance et le traitement de multiples données ou informations. La première contribution de cette thèse est SM2PH Central et sa capacité de générer des instances. SM2PH Central constitue notre centre de référence en ligne pour toutes les protéines humaines intégrant des niveaux d’informations qui vont des aspects génomiques, structuraux, fonctionnels ou évolutifs aux aspects de transcriptomique, interactomique, protéomique ou métabolomique. La deuxième contribution est MSV3d, une ressource d’annotation multi-niveau (propriétés physico-chimiques, fonction, évolution, structure) des mutations humaines connues. MSV3d fournit l’ensemble des connaissances exploitées par la troisième contribution de cette thèse à savoir KD4v, notre base d’extraction de connaissances pour prédire l’impact phénotypique d’une mutation. La base de connaissances de KD4v induite par la Programmation Logique Inductive contient des règles exploitables par un humain ou un ordinateur et des facteurs prédictifs caractérisant les mutations neutres ou délétères. Enfin, l’ultime contribution de cette thèse est liée au développement de GEPeTTO, un prototype de priorisation de gènes. Une application biologique a été réalisée. Nous avons étudié la cécité nocturne en utilisant SM2PH Central, en combinaison avec le service d’annotation de MSV3d et la méthode de prédiction KD4v pour analyser le gène GPR179 et ses deux mutations nouvellement identifiées. / Responding to the need to better understand the relationships linking the genotype to the molecular and clinical phenotype, we have developed a new bioinformatics infrastructure that unites, in a single system, the collection, the management, the maintenance and the processing of multiple data or information. The first contribution of this thesis is SM2PH Central and its ability to generate instances. SM2PH Central is our online reference center for all human proteins including many levels of information such as genomics, structural, functional and evolutionary aspects of transcriptomics, interactomics, proteomics or metabolomics. The second contribution is MSV3d, a multi-level annotation resource (physico-chemical properties, function, evolution, structure) of known human mutations. MSV3d provides the knowledge used by the third contribution of this thesis namely KD4v, our knowledgebase extraction to predict the phenotypic effect of a mutation. The KD4v knowledgebase computed by Inductive Logic Programming contains the rules describing the information that can be either exploited by a human or a computer, and the predictors characterizing neutral or deleterious mutations. The last contribution of this thesis is related to the development of GEPeTTO, a prototype of the prioritization of genes. Finally, these tools (SM2PH Central, MSV3d, KD4v) allowed us in the context of patients data analysis to confirm the implication of GPR179 as a new gene responsible for congenital stationary night blindness.

No description available.

La déficience intellectuelle (DI) est souvent associée à d’autres signes cliniques morphologiques et psychiatriques mais cette comorbidité est peu caractérisée pour la DI associée à un gène donné. Ainsi les mutations du gène p21-activated kinase 3 (PAK3) sont responsable d’un large spectre clinique, allant de la DI légère à des DI sévères associées parfois à des malformations du cerveau. Nous avançons l’hypothèse que les différentes mutations d’un même gène peuvent affecter divers paramètres biochimiques et affecter de manière différentielle les voies de signalisation impliquées dans la plasticité synaptique et dans le développement du cerveau. Pour valider notre hypothèse, nous avons caractérisé une nouvelle mutation responsable d’une déficience intellectuelle sévère associée à une agénésie du corps calleux et une microcéphalie. Cette mutation supprime l’activité kinase, n’affecte pas la stabilité de la protéine et augmente l’interaction avec un GEF de la famille PIX. Ces derniers résultats identifient une nouvelle voie de signalisation impactée par certaines mutations de PAK3. L’expression de ce variant modifie la morphologie cellulaire et la dynamique des adhésions focales, ainsi que les propriétés migratoires des cellules, ce qui pourraient relier les défauts biochimiques aux défauts de certaines fonctions cellulaires. De manière intéressante, ces caractéristiques sont aussi retrouvées pour un autre variant responsable d’une clinique également très sévère. Nous avons également caractérisé d’autres mutations associées à des phénotypes moins sévères. La synthèse de nos résultats nous permet ici de proposer un modèle explicatif de la relation génotype-phénotype pour les mutations de déficience intellectuelle liées au gène PAK3, intégrant des défauts neurodéveloppementaux et de plasticité synaptique. / Intellectual Disability (ID) is often associated with other morphological and psychiatric clinical signs, but this comorbidity is poorly characterized for ID associated with a given gene. Thus mutations of the p21-activated kinase 3 (PAK3) gene are responsible for a broad clinical spectrum, ranging from mild ID to severe ID, sometimes associated with brain malformations. We hypothesize that different mutations of the same gene may affect various biochemical parameters and differentially affect the signaling pathways involved in synaptic plasticity and brain development. To validate our hypothesis, we characterized a new mutation responsible for a severe intellectual disability associated with agenesis of the corpus callosum and microcephaly. This mutation suppresses kinase activity, does not affect protein stability and increases the interaction with a GEF of the PIX family. These latest results identify a new signaling pathway impacted by certain PAK3 mutations. The expression of this variant modifies the cellular morphology and the dynamics of the focal adhesions, as well as cell migratory properties, which could link the biochemical defects to those of certain cell functions. Interestingly, these features are also found for another variant responsible for a very similar severe clinical spectrum. We have also characterized other mutations associated with less severe phenotypes. The synthesis of our results allows us to propose an explanatory model of the genotype-phenotype relationship integrating neurodevelopmental and synaptic plasticity defects for intellectual disability and other clinical traits associated to the PAK3 gene mutations.

Most genome-wide association studies search for genetic variants associated to a single trait of interest, despite the main interest usually being the understanding of a complex genotype-phenotype network. Furthermore, many studies collect data on multiple phenotypes, each measuring a different aspect of the biological system under consideration, therefore it can often make sense to jointly analyze the phenotypes. However this is rarely the case and there is a lack of well developed methods for multiple phenotype analysis. Here we propose novel approaches for genome-wide association analysis, which scan the genome one SNP at a time for association with multivariate traits. The first half of this thesis focuses on an analytic model averaging approach which bi-partitions traits into associated and unassociated, fits all such models and measures evidence of association using a Bayes factor. The discrete nature of the model allows very fine control of prior beliefs about which sets of traits are more likely to be jointly associated. Using simulated data we show that this method can have much greater power than simpler approaches that do not explicitly model residual correlation between traits. On real data of six hematological parameters in 3 population cohorts (KORA, UKNBS and TwinsUK) from the HaemGen consortium, this model allows us to uncover an association at the RCL locus that was not identified in the original analysis but has been validated in a much larger study. In the second half of the thesis we propose and explore the properties of models that use priors encouraging sparse solutions, in the sense that genetic effects of phenotypes are shrunk towards zero when there is little evidence of association. To do this we explore and use spike and slab (SAS) priors. All methods combine both hypothesis testing, via calculation of a Bayes factor, and model selection, which occurs implicitly via the sparsity priors. We have successfully implemented a Variational Bayesian approach to fit this model, which provides a tractable approximation to the posterior distribution, and allows us to approximate the very high-dimensional integral required for the Bayes factor calculation. This approach has a number of desirable properties. It can handle missing phenotype data, which is a real feature of most studies. It allows for both correlation due to relatedness between subjects or population structure and residual phenotype correlation. It can be viewed as a sparse Bayesian multivariate generalization of the mixed model approaches that have become popular recently in the GWAS literature. In addition, the method is computationally fast and can be applied to millions of SNPs for a large number of phenotypes. Furthermore we apply our method to 15 glycans from 3 isolated population cohorts (ORCADES, KORCULA and VIS), where we uncover association at a known locus, not identified in the original study but discovered later in a larger one. We conclude by discussing future directions.

Die b -Thalassämie gehört weltweit zu den häufigsten monogenen Erbkrankheiten. Die Thalassämien treten endemisch in der Bevölkerung des Mittelmeerraumes, in Westafrika und in weiten Teilen Asiens auf. In der einheimischen Bevölkerung der Bundesrepublik Deutschland gehört die homozygote Form der b -Thalassämie zu den seltenen Erkrankungen. Häufiger ist das Auftreten der heterozygoten Form, die als Differentialdiagnose der mikrozytären, hypochromen Anämie eine besondere Rolle spielt. Blutproben von 214 deutschen Personen mit einer heterozygoten b -Thalassämie wurden mittels Allel-spezifischer Oligonukleotid-Hybridisierung, Restriktionsanalyse und direkter Sequenzierung PCR-amplifizierter DNA analysiert. Insgesamt konnten 96,3 % (206/214) der Proben molekular charakterisiert werden. Die mediterranen Mutationen stellen einen Anteil von etwa 2/3 aller identifizierten Veränderungen, häufig sind insbesondere NS 39, IVS1-110 G ® A und IVS1-1 G ® A. Das übrige Mutationsspektrum setzt sich aus sehr seltenen Mutationen (IVS1-1 G ® T, IVS1-2 T ® G, IVS1-2 T ® C, NS 15 G ® A, NS 121 G ® T, FS 8/9 +G, FS 44 -C, FS 51 -C, FS 82/83 -G, Initiations-Kodon-Mutationen ATG ® ACG/ ® GTG/ ® ATA) und einer neuen Mutation (IVS1-129 A ® G) zusammen. In 6 Fällen konnte nach vollständiger molekularer Analyse kein Gendefekt als Ursache der b -Thalassämie gefunden werden. Diese Probanden könnten b -Thalassämiedeterminanten tragen, die nicht an den b -Globingen-Komplex gekoppelt sind oder regulative Sequenzen außerhalb des b -Globingens darstellen. Die erhobenen Daten zeigen, daß der Ursprung der b -Thalassämie in der deutschen Bevölkerung in den Mittelmeerländern liegt, ein Drittel der Fälle scheint sich jedoch lokal entwickelt zu haben. / The b -thalassemia belongs to the most common monogenic disorders worldwide. Endemically in the Mediterranean population, some parts of Asia and Western Africa, b -thalassemia is a rare disease in Germany. Nevertheless, heterozygous forms of b -thalassemia minor occur more frequently in the German population and should be considered in the differential diagnosis of hypochromic anemia. To investigate the molecular biological background of b -thalassemia in Germany, 214 non-immigrant German individuals suffering from heterozygous b -thalassemia were characterized by allele-specific oligonucleotid hybridization, restriction analysis and sequencing of the b -globin gene. By these techniques, 26 different mutations were identified. Most frequently, the Mediterranean mutations NS 39, IVS1-110 G ® A, and IVS1-1 G ® A were detected. Although otherwise rare, the frameshift mutation of codon 83 (FS 83 -G) was also relatively common (5 %) in the analyzed population. Other previously described mutations (IVS1-1 G ® T, IVS1-2 T ® G, IVS1-2 T ® C, NS 15 G ® A, NS 121 G ® T, FS 8/9 +G, FS 44 -C, FS 51 -C, initiation codon mutation ATG ® ACG/ ® GTG/ ® ATA) were demonstrated in < 10 individuals. Interestingly, sequence analysis identified a novel mutation affecting position -2 of the splice acceptor site (IVS1-129 A ® G). In 6 individuals diagnosed as heterozygous b -thalassemia, a mutation of the b -globin gene could not be demonstrated. The data indicate the b -thalassemia to be introduced from the Mediterranean population into Germans in two-thirds of the cases whereas the remaining third probably is of local origin.

Die genetischen Polymorphismen der humanen Biotransformationsenzyme Glutathion-S-Transferase Theta 1 (GSTT1-1) und Arylamin-N-Acetyltransferase 1 (NAT1) wurden zu Beginn der neunziger Jahre entdeckt. Es besteht derzeit ein großes Interesse an Untersuchungen zur Häufigkeit der Allele, zu deren phänotypischen Konsequenzen und pharmakologisch-toxikologischer Relevanz. Für die Untersuchungen in dieser Arbeit standen die Blutproben von 314 gesunden, deutschen Probanden mit bekanntem GSTT1- und/oder NAT1-Genotyp zur Verfügung. Es wurden Methoden etabliert und validiert, um im Hämolysat die Reaktionsgeschwindigkeiten bei der Umsetzung des GSTT1-1-spezifischen Substrats Dichlormethan sowie des NAT1-spezifischen Substrats p-Aminobenzoesäure mit vertretbarem Laboraufwand zu bestimmen. In der vorliegenden Arbeit wurde eine vollständige Übereinstimmung zwischen der homozygoten GSTT1-Gendeletion und dem defizienten Phänotyp bei 19,3% der Individuen gefunden. Bei 80,7% der Probanden war durch Genotypisierung mindestens ein GSTT1*A-Allel identifiziert worden. Mit Hilfe der Phänotypisierung konnten in dieser Gruppe zwei Phänotypen, der intermediäre und der hoch aktive Phänotyp, voneinander abgegrenzt werden. Damit bestand der Vorteil der Phänotypisierung darin, eine trimodale Verteilung der GSTT1-1-Aktivität nachweisen zu können. Dies wurde in der vorliegenden Arbeit erstmalig in einer größeren deutschen Population gezeigt. Weiterhin wurden in dieser Arbeit untersucht, ob zwei Phosphonsäurediester des Glutathions, die sich als kompetitive bzw. nicht-kompetitive Hemmstoffe anderer GST-Isoenzyme erwiesen hatten, sowie der Arzneistoff Tactin, ein Medikament zur Behandlung des Mobus Alzheimer eine Hemmwirkung auf die GSTT1-1-vermittelte Umsetzung von Dichlormethan besitzen. Gegenwärtig sind 24 verschiedene NAT1-Allele bekannt, wobei einige davon sehr selten auftreten. In der hier verwendeten deutschen Population waren sechs NAT1-Allele identifiziert worden. In den Blutproben der 105 Probanden wurde die funktionelle Konsequenz dieser Allele bestimmt. In vorliegender Arbeit wurde erstmalig für einen homozygoten Träger des NAT1*15-Allels das Fehlen jeglicher Enzymaktivität nachgewiesen. Bezüglich der Häufigkeit der GSTT1-Gendefizienz sowie des NAT1*11-Allels wurden in vorliegender Arbeit zwischen europäischen, d.h. einander ethnisch nahestehenden Bevölkerungsgruppen statistisch signifikante Unterschiede gefunden. / The genetic polymorphisms of the glutathione S-transferase theta 1-1 (GSTT1-1) and the arylamine N-acetyltransferase 1 (NAT1) were found in the beginning of the 90's. There is a great interest in genotype-phenotype relations in individuals and in pharmacological and toxicological consequences of the polymorphisms. In this work, hemolysate of 314 healthy German volunteers was used for several genotyping and phenotyping methods. A concordance between the homozygous GSTT1 gene deletion and the enzyme deficiency in 27 of 140 individuals (19,3%)was found. In 80,7% of the volunteers a discrimination between intermediate and rapid metabolizers was possible in a German population for the first time. In addition it was proved, if the ex-vivo metabolism of dichloromethane, catalyzed by GSTT1-1, is inhibited by phosphono-analoga of glutathione or tacrine, a drug for treatment of Alzheimers' disease. The NAT1 polymorphism is characterized by several point mutations and deletions or insertions of oligonucleotides. 24 NAT1 alleles are known so far. In this work, the functional consequences of various NAT1 allele combinations in the genotypes of 105 individuals were determinated. There were found interethnic differences in the frequency of the NAT1*11 allele and the frequency of the homozygous gene deletion between the German and other Caucasien populations.